Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I multiple ascending dose study of intravenous NPT189 in healthy volunteers
NL-OMON48151Phase 1Completed
- Sponsor
- Proclara Biosciences
- Start
- Feb 2019
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in amyloidosis comparing NPT189 with Placebo (2 arms). Primary endpoint: Safety and tolerability. Started Feb 2019; status: completed.
02
Drugs
PCS-01
03
Conditions
amyloidosis
Beyond the preview
Go deeper on NL-OMON48151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48151.